Resource Tracking
The HIV
Vaccines and Microbicides Resource Tracking
Working Group
Report 2010
Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009.
The report finds stability in
funding for HIV prevention research from
2008 to 2009. HIV vaccines continued to receive
the majority of
funding, with a total of US$868 million, which
was equal to 2008
funding levels. Investment in microbicides was
US$236 million, a
decline of 3 percent from 2008 levels. Funding
for PrEP increased by 18
percent over 2008 levels to US$52 million.
The stability in funding is encouraging, given a 10 percent decrease in funding for AIDS vaccine research seen in 2008, but the Working Group identified several areas of concern if funding remains flat, including escalating costs of late-stage clinical research, dependency on a small group of funders and a lack of diversity in funders.
The HIV Vaccines and Microbicides Resource Tracking Working Group Report 2009
Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008
Released in Cape Town at the IAS
conference, this year's report shows
that in 2008, US$868 million was spent on
vaccines, US$244 million on
microbicides, and US$81 million on other new
prevention options such as
pre-exposure prophylaxis using antiretroviral
drugs (PrEP) and the
rollout of medical male circumcision. These
amounts reflect a 10% decline in funding for
vaccines and an 8%
increase in microbicides research funding
between 2007 and 2008.
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs, and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it is critical that funding for HIV prevention research funding is sustained.
AVAC serves as the secretariat for the HIV Vaccines and Microbicides Resource Tracking Working Group, which also includes the Alliance for Microbicide Development, the International AIDS Vaccine Initiative, and UNAIDS. This new report along with archives of the Working Group's previous reports can be found at www.hivresourcetracking.org.
Report 2010
Advancing the Science in a Time of Fiscal Constraint: Funding for HIV Prevention Technologies in 2009.
The stability in funding is encouraging, given a 10 percent decrease in funding for AIDS vaccine research seen in 2008, but the Working Group identified several areas of concern if funding remains flat, including escalating costs of late-stage clinical research, dependency on a small group of funders and a lack of diversity in funders.
The HIV Vaccines and Microbicides Resource Tracking Working Group Report 2009
Adapting to Realities: Trends in HIV Prevention Research Funding 2000 to 2008
The year 2008 saw a range of funding changes from the previous year, both within and among different technologies. The overall trend for almost a decade, though, has been of increasing investment for all experimental biomedical prevention strategies. However, recent changes in scientific priorities, competing global health needs, and the downturn in the economy could impact future funding decision-making. To ensure new HIV prevention options are developed and implemented, it is critical that funding for HIV prevention research funding is sustained.
AVAC serves as the secretariat for the HIV Vaccines and Microbicides Resource Tracking Working Group, which also includes the Alliance for Microbicide Development, the International AIDS Vaccine Initiative, and UNAIDS. This new report along with archives of the Working Group's previous reports can be found at www.hivresourcetracking.org.